In lung cancers with amplifying or mutated ERBB2, ado-trastuzumab emtansine (T-DM1) was also validated in the PDX model before becoming the first ADC approved in China (Li et al., 2020). The gene discussed is ERBB2; the disease is lung carcinoma.